OSE Immunotherapeutics
Clinical-stage biotech developing immune therapies for oncology and inflammation.
OSE | PA
Overview
Corporate Details
- ISIN(s):
- FR0012127173 (+2 more)
- LEI:
- 969500HIUWVGY6NZSM05
- Country:
- France
- Address:
- 22 BOULEVARD BENONI GOULLIN, 44200 NANTES
- Sector:
- Manufacturing
Description
OSE Immunotherapeutics is a clinical-stage biotechnology company focused on developing and partnering first-in-class therapies that control the immune system. The company's pipeline is concentrated in two key areas: immuno-oncology (IO) and immuno-inflammation (I&I). In immuno-oncology, its research aims to help the immune system recognize and target tumors. In immuno-inflammation, it develops treatments for autoimmune diseases and chronic inflammation by regulating immune responses. OSE Immunotherapeutics utilizes proprietary drug discovery platforms to generate novel product candidates, including monoclonal antibodies and RNA therapeutics, and collaborates with pharmaceutical partners to advance its assets through clinical development.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2024-11-04 07:30 |
OSE Immunotherapeutics Annonce des Résultats Cliniquement Probants et Statistiq…
|
French | 296.7 KB | ||
| 2024-11-04 07:30 |
OSE Immunotherapeutics Announces Statistically Significant and Clinically Meani…
|
English | 320.3 KB | ||
| 2024-10-17 18:00 |
OSE Immunotherapeutics présente une nouvelle technologie bispécifique de « Cis-…
|
French | 302.4 KB | ||
| 2024-10-17 18:00 |
OSE Immunotherapeutics Presents New “Cis-Demasking” Bispecific Technology for t…
|
English | 328.8 KB | ||
| 2024-10-02 18:00 |
Informations relatives au nombre total de droits de vote et d’actions composant…
|
French | 228.5 KB | ||
| 2024-09-26 18:00 |
OSE Immunotherapeutics Announces Historic H1 2024 Results and Provides Corporat…
|
English | 487.7 KB | ||
| 2024-09-26 18:00 |
OSE Immunotherapeutics annonce des résultats semestriels 2024 remarquables et f…
|
French | 424.2 KB | ||
| 2024-09-26 16:38 |
RAPPORT FINANCIER SEMESTRIEL
|
French | 930.8 KB | ||
| 2024-09-10 07:30 |
OSE Immunotherapeutics Announces Global Launch of Artemia Phase 3 Registration …
|
English | 329.4 KB | ||
| 2024-09-10 07:30 |
OSE Immunotherapeutics annonce le lancement international d’Artemia, l’étude de…
|
French | 304.0 KB | ||
| 2024-09-03 18:00 |
Informations relatives au nombre total de droits de vote et d’actions composant…
|
French | 221.9 KB | ||
| 2024-08-02 18:00 |
Informations relatives au nombre total de droits de vote et d’actions composan…
|
French | 230.8 KB | ||
| 2024-07-24 08:55 |
OSE Immunotherapeutics annonce des résultats positifs d'efficacité de Lusvertik…
|
French | 283.8 KB | ||
| 2024-07-24 08:55 |
OSE Immunotherapeutics Announces Positive Efficacy Results for Lusvertikimab in…
|
English | 316.2 KB | ||
| 2024-07-03 18:00 |
OSE Immunotherapeutics et Boehringer Ingelheim poursuivent l’avancée du dévelop…
|
French | 257.5 KB |
Automate Your Workflow. Get a real-time feed of all OSE Immunotherapeutics filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for OSE Immunotherapeutics
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for OSE Immunotherapeutics via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2024-06-19 | N/A | Other | Other | 10,000 | 35,700.00 EUR |
| 2024-06-17 | N/A | Other | Other | 10,000 | 35,800.00 EUR |
| 2024-06-17 | N/A | Other | Other | 10,000 | 35,700.00 EUR |
| 2024-06-13 | N/A | Other | Sell | 6,369 | 45,879.09 EUR |
| 2024-06-03 | N/A | Other | Sell | 40,000 | 314,512.00 EUR |
Peer Companies
